Abbott
Financials
Estimates*
USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Revenues | 34.6b | 43.1b | 43.7b | 40.1b | 41.7b | 44.8b | 48.1b |
% growth | 8 % | 24 % | 1 % | (8 %) | 4 % | 7 % | 7 % |
EBITDA | 7.6b | 10.7b | 10.7b | 10.6b | 10.7b | 11.6b | 12.9b |
% EBITDA margin | 22 % | 25 % | 25 % | 26 % | 26 % | 26 % | 27 % |
Profit | 4.5b | 7.1b | 6.9b | 5.7b | 5.8b | 6.8b | 7.8b |
% profit margin | 13 % | 16 % | 16 % | 14 % | 14 % | 15 % | 16 % |
EV / revenue | 5.8x | 5.8x | 4.5x | 5.0x | 4.9x | 4.5x | 4.1x |
EV / EBITDA | 26.3x | 23.2x | 18.5x | 18.8x | 19.0x | 17.2x | 15.2x |
R&D budget | 2.4b | 2.7b | 2.9b | 2.7b | - | - | - |
R&D % of revenue | 7 % | 6 % | 7 % | 7 % | - | - | - |
Source: Dealroom estimates
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
N/A | N/A | IPO | |
N/A | $6.7m | Post IPO Debt | |
N/A | $100k | Post IPO Debt | |
Total Funding | - |
Related Content
Recent News about Abbott
EditAbbott Laboratories is a global healthcare company dedicated to improving lives through innovative medical technologies and health solutions. The company operates in several key areas, including cardiovascular health, diabetes management, diagnostic testing, nutrition, and neuromodulation for chronic pain and movement disorders. Abbott's mission is to create life-changing technologies that are accessible and affordable, aiming to help people live their best lives.
Abbott serves a diverse range of clients, including hospitals, healthcare professionals, and patients. The company operates in the global healthcare market, which encompasses various sectors such as medical devices, diagnostics, and nutrition. Abbott's business model focuses on research and development to create advanced medical products and solutions that address critical health needs.
The company generates revenue through the sale of its medical devices, diagnostic tests, and nutritional products. For instance, Abbott's cardiovascular technologies help doctors manage heart health more effectively, while its diabetes care products allow patients to monitor their glucose levels accurately without painful fingersticks. In diagnostics, Abbott provides essential testing solutions that deliver timely information for better decision-making. Additionally, the company's neuromodulation products offer relief for chronic pain and movement disorders by targeting specific areas of the nervous system.
Abbott is also committed to sustainability, with a 2030 Sustainability Plan that prioritizes designing technologies for greater access and affordability. This commitment underscores the company's broader goal of making a positive impact on global health and well-being.
Keywords: healthcare, medical devices, diagnostics, cardiovascular, diabetes management, neuromodulation, chronic pain, nutrition, sustainability, innovation.